The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness

Meredith I. Williams, Katherine J. Donohue, Pascual Sanz, Souad Messahel, Jose M. Serratosa, Jordi Duran, Roberto Michelucci, Lorenzo Muccioli, Antonio Delgado-Escueta, Viet Huong V. Nguyen, Berge A. Minassian, Matthew S. Gentry*

*Autor corresponent d’aquest treball

Producció científica: Article en revista indexadaArticleAvaluat per experts

Resum

Lafora disease (LD) is a fatal childhood progressive myoclonus epilepsy and glycogen storage disease that is caused by recessive mutations in either EPM2A or EPM2B. The hallmarks of LD are cytoplasmic, aberrant glycogen-like aggregates, called Lafora bodies (LBs), that drive disease progression. The 9th Annual Lafora Science Symposium was held in San Diego, California and brought together over 70 researchers, clinicians, academic trainees, and friends and family members of patients with LD and 80 attendees joined virtually. This symposium focused primarily on international collaborations for therapeutic development and biomarker identification and strategies for preparing the Lafora community for upcoming clinical trials.

Idioma originalAnglès
Número d’article110654
RevistaEpilepsy and Behavior
Volum171
DOIs
Estat de la publicacióPublicada - d’oct. 2025

Fingerprint

Navegar pels temes de recerca de 'The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness'. Junts formen un fingerprint únic.

Com citar-ho